Brinker Capital Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Brinker Capital Investments’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97M	Sell	24,870 -36,474	-59%	-$2.74M	0.02%	806
2026 Q1	$4.61M	Buy	61,344 +37,770	+160%	+$2.98M	0.04%	390
2025 Q4	$1.86M	Buy	23,574 +13,612	+137%	+$1.02M	0.01%	890
2025 Q3	$652K	Buy	9,962 +4,362	+78%	+$213K	0.01%	1432
2025 Q2	$221K	Buy	+5,600	New	+$183K	﹤0.01%	1843
2020 Q1	–	Sell	-138	Closed	-$8K	–	511
2019 Q4	$8K	Hold	138	–	–	﹤0.01%	591
2019 Q3	$8K	Buy	+138	New	+$8.99K	﹤0.01%	591

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brinker Capital Investments's IONS Position: Q2 2026 in Review

Brinker Capital Investments reduced its Ionis Pharmaceuticals (IONS) stake by 59% in Q2 2026, selling an estimated $2.74M and leaving 24,870 shares worth $1.97M. The position accounts for 0.02% of the portfolio, ranked #806.

Brinker Capital Investments first reported a position in IONS in Q3 2019 and has held it in 7 quarters since. The position peaked at $4.61M in Q1 2026. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Brinker Capital Investments held 24,870 shares of Ionis Pharmaceuticals worth $1.97M as of Q2 2026.
Brinker Capital Investments sold 36,474 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.74M.
Ionis Pharmaceuticals made up 0.02% of Brinker Capital Investments's portfolio in Q2 2026, its #806 holding.
Brinker Capital Investments first reported a position in Ionis Pharmaceuticals in Q3 2019 and has held it in 7 quarters since.
Brinker Capital Investments's Ionis Pharmaceuticals position peaked at $4.61M in Q1 2026.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.